Cangrelor

CAT: 0804-HY-19638Size: 1 EachDry Ice: NoHazardous: No
CAT#: HY-19638Size: 1 Each
Selected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP) -induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist[1][2].
CAS Number
[163706-06-7]
Product Name Alternative
AR-C69931MX
UNSPSC
12352005
Hazard Statement
H315-H319-H320
Target
P2Y Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/cangrelor.html
Solubility
10 mM in DMSO
Smiles
CSCCNC1=C2C(N([C@H]3[C@H](O)[C@H](O)[C@@H](COP(OP(C(Cl)(Cl)P(O)(O)=O)(O)=O)(O)=O)O3)C=N2)=NC(SCCC(F)(F)F)=N1
Molecular Formula
C17H25Cl2F3N5O12P3S2
Molecular Weight
776.36
Precautions
P264-P280-P302+P352-P305+P351+P338-P362
References & Citations
[1]Bhattad VB, , et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019;7 (17) :408.|[2]Zhan T, Wei T, et al. Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice. Mol Immunol. 2020;120:83-92.|[3]Bekő K, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain. J Thromb Haemost. 2017;15 (6) :1223-1235.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
P2Y12 Receptor

Related Products

CatalogName